![]() Following the Titration Period, participants will continue to receive the same dose in the Maintenance Period. Participants will receive soticlestat or matching placebo based on their weight in the 4-week Titration Period. Placebo (dummy inactive pill - this is a tablet/mini-tablet that looks like the study drug but has no active ingredient). ![]() Participants will be randomly assigned (by chance, like flipping a coin) in a 1:1 ratio to receive standard of care (SOC) plus one of the following adjunctive therapies which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need): ![]() The study will enroll approximately 234 patients. Soticlestat will be assessed for efficacy, safety, and tolerability in pediatric and adult participants with Lennox-Gastaut syndrome (LGS). The drug being tested in this study is called soticlestat (TAK-935).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |